Salient Pharma ApS: Financial statements 2024
CVR: 36900709
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Salient Pharma ApS (CVR 36900709) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -124,372 and a net result of DKK -202,180 compared with DKK -304,925 the year before. Equity in the 2024 report amounted to DKK -1,125,665.
- Gross Profit
- DKK -124,372
- Profit/Loss
- DKK -202,180
- Equity
- DKK -1,125,665
- Total Assets
- DKK 19,023
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -124 t. | -202 t. | -1.1 mio. | 0 |
| 2023 | - | -233 t. | -305 t. | -1.2 mio. | 0 |
| 2022 | - | -126 t. | -188 t. | -981 t. | 0 |
| 2021 | - | -259 t. | -301 t. | -793 t. | 0 |
| 2020 | - | -485 t. | -902 t. | -492 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Salient Pharma ApS has published its annual report for 2023. Gross profit came to DKK -233,306, and the net result was DKK -304,925.
About Salient Pharma ApS
Salient Pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Ulrik Spork. The board consists of Helle Bøwadt, Søren Wang Petersen and Ulrik Spork. The company is owned by HB-MEDICAL HOLDING ApS, CAND.PHARM. POVL M. ASSENS FOND and SPORCON LIFESCIENCE ADVISORS ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -129,889 and a net result of DKK -218,345 compared with DKK -202,180 the year before. Equity in the 2025 report amounted to DKK -1,344,010.